Filing Details
Protagenic Therapeutics, Inc.\new (NASDAQ:PTIX) filed a Form 8-K with the Securities and Exchange Commission on August 20, 2026, disclosing a material event.
8k filedNASDAQ:PTIX
Protagenic Therapeutics, Inc.\new (PTIX) Reports Material Event to SEC
Protagenic Therapeutics, Inc.\new (NASDAQ:PTIX) filed a Form 8-K with the Securities and Exchange Commission on August 20, 2026, disclosing a material event.
At publication ·
What changed
Protagenic Therapeutics, Inc.\new (NASDAQ:PTIX) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Protagenic Therapeutics, Inc. (NASDAQ: PTIX) filed a Form 8-K with the SEC on August 20, 2026, disclosing a material event that shareholders should be aware of.
- The company's stock trades at $0.60 per share with a market capitalization of $3.0 million.
- The article does not specify the nature of the material event, which could involve leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance.
Market Context
Protagenic Therapeutics, Inc.\new's stock currently trades at $0.60 with a market capitalization of $3.0M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Protagenic Therapeutics, Inc.\new's stock.
All SEC filings for Protagenic Therapeutics, Inc.\new are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View PTIX Stock Page
Frequently Asked Questions
Where can I read PTIX's SEC filings?
Browse all filings on our PTIX SEC filings page.
What types of SEC filings does Protagenic Therapeutics, Inc.\new file?
Public companies like Protagenic Therapeutics, Inc.\new file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.